An updated review of a novel method for examining P53 mutations in different forms of cancer

Shomali, Navid; Kamrani, Amin; Nasir, Hira; Heris, Javad Ahmadian; Shahabi, Parviz; Yousefi, Mehdi; Mohammadinasab, Reza; Sadeghvand, Shahram; Akbari, Morteza

doi:10.1016/j.prp.2023.154585

Cited by 3 publications

(2 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among cell biologists, one of the topics they study the most is likely cell death, specifically apoptosis. Knowing how apoptosis functions in illness circumstances is crucial since it not only provides insight into the pathophysiology of a disease but may also provide treatment recommendations 115 . The balance between cell division and death is thrown off in cancer, and cells that ought to die do not get the signal to do so and any point during the apoptotic process can be problematic 116 …”

Section: Dgcr5 Role In Cancer Cell Apoptosismentioning

confidence: 99%

The role of long noncoding RNA DGCR5 in cancers: Focus on molecular targets

Al‐Hawary,

Rodrigues,

Bangali

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are major components of cellular transcripts that are emerging as important players in various biological pathways. Due to their specific expression and functional diversity in a variety of cancers, lncRNAs have promising applications in cancer diagnosis, prognosis, and therapy. Studies have shown that lncRNA DiGeorge syndrome critical region gene 5 (DGCR5) with high specificity and accuracy has the potential to become biomarkers in cancers. LncRNA DGCR5 can be noninvasively extracted from body fluids, tissues, and cells, and can be used as independent or auxiliary biomarkers to improve the accuracy of diagnosis or prognosis. Now, the underlying mechanisms of lncRNAs such as DGCR5 were explored as therapeutic targets, which have been investigated in clinical trials of several cancers. The DGCR5 lacks an appropriate animal model, which is necessary to gain greater knowledge of their functions. While some studies on the uses of DGCR5 have been carried out, the small sample size makes them unreliable. In this review, we presented a compilation of recent publications addressing the potential of lncRNA DGCR5 that could be considered as biomarkers or therapeutic targets, with the hopes of providing promised implications for future cancer therapy.

show abstract

Section: Dgcr5 Role In Cancer Cell Apoptosismentioning

confidence: 99%

The role of long noncoding RNA DGCR5 in cancers: Focus on molecular targets

Al‐Hawary,

Rodrigues,

Bangali

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…Immune cell-derived exosomes, which promote the interplay between innate and adaptive immunity, can be used to control the growth and spread of cancer. 8 B cells are emerging as a potentially significant immune cell source of exosomes in vivo. 9 Exosomes generated from B cells have been shown to be important in the pathophysiology of diseases like cancer by inhibiting T cells which attack tumors.…”

Section: Introductionmentioning

confidence: 99%

Leukemia cancer cells and immune cells derived‐exosomes: Possible roles in leukemia progression and therapy

Salman,

Mohammad

2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

Exosomes have a significant impact on tumor survival, proliferation, metastasis, and recurrence. They also open up new therapeutic options and aid in the pathological identification and diagnosis of cancers. Exosomes have been shown in numerous studies to be essential for facilitating cell‐to‐cell communication. In B‐cell hematological malignancies, the proteins and RNAs that are encased by circulating exosomes are thought to represent prospective sources for therapeutic drugs as well as biomarkers for diagnosis and prognosis. Additionally, exosomes can offer a “snapshot” of the tumor and the metastatic environment at any given point in time. In this review study, we concluded that leukemia‐derived exosomes could be utilized as prognostic, diagnostic, and therapeutic biomarkers for individuals suffering from leukemia. Moreover, clinical studies have demonstrated that immune cells like dendritic cells create exosomes, which have the ability to activate the immune system against leukemia.

show abstract

The pattern-based interpretation of p53 immunohistochemical expression as a surrogate marker for TP53 mutations in colorectal cancer

Osakabe,

Yamada,

Sugimoto

et al. 2024

Virchows Arch

View full text Add to dashboard Cite

Mutations in the TP53 gene, most commonly observed in colorectal cancer (CRC), play an essential role in colorectal carcinogenesis. Although p53 immunohistochemical (IHC) expression patterns have been argued to serve as an excellent surrogate marker for TP53 mutations, its performance has not been confirmed in CRC. We aimed to determine whether p53 IHC expression patterns accurately predict TP53 mutation status as examined by next-generation sequencing (NGS). We performed p53 IHC and sequencing of TP53 by NGS in 92 CRC cases with a microsatellite stable phenotype to investigate the correlation between TP53 mutation status and p53 IHC expression. The concordance between p53 IHC and TP53 mutation was 84/92 (91.3%) overall. However, 6 mutant cases were found in 39 cases with a wild-type IHC pattern. Additionally, there were two discordant cases in which an abnormal p53 IHC pattern (overexpression or cytoplasmic pattern) was found, while NGS detected wild-type p53. Therefore, the optimized p53 IHC performs well and serves as a surrogate test for TP53 mutation in CRC cases. Furthermore, it demonstrates excellent reproducibility between two independent experienced pathologists and may have novel clinical utility for molecular classification algorithms in CRC. We suggest that the four-tier classification of p53 IHC patterns is helpful to evaluate molecular colorectal carcinogenesis.

show abstract

An updated review of a novel method for examining P53 mutations in different forms of cancer

Cited by 3 publications

References 71 publications

The role of long noncoding RNA DGCR5 in cancers: Focus on molecular targets

The role of long noncoding RNA DGCR5 in cancers: Focus on molecular targets

Leukemia cancer cells and immune cells derived‐exosomes: Possible roles in leukemia progression and therapy

The pattern-based interpretation of p53 immunohistochemical expression as a surrogate marker for TP53 mutations in colorectal cancer

Contact Info

Product

Resources

About